Provided by Tiger Fintech (Singapore) Pte. Ltd.

Keros Therapeutics, Inc.

14.49
+0.24001.68%
Post-market: 14.490.00000.00%16:09 EDT
Volume:377.09K
Turnover:5.44M
Market Cap:588.52M
PE:132.98
High:14.58
Open:14.25
Low:14.18
Close:14.25
Loading ...

Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024

Business Wire
·
28 Jan

Keros Therapeutics Stock Plunges 81% in 3 Months: Here's Why

Zacks
·
23 Jan

Keros Therapeutics (KROS) Soars 5.1%: Is Further Upside Left in the Stock?

Zacks
·
22 Jan

Keros Therapeutics Cut to Neutral From Overweight by Cantor Fitzgerald

Dow Jones
·
22 Jan

Keros to Receive $200 Million From Takeda In Connection to Elritercept License Deal

MT Newswires Live
·
21 Jan

BRIEF-Keros Therapeutics Announces Effectiveness Of Global License Agreement With Takeda

Reuters
·
21 Jan

Cantor Fitzgerald Downgrades Keros Therapeutics to Neutral From Overweight

MT Newswires Live
·
21 Jan

Keros Therapeutics Inc - Takeda to Make $200 Million Upfront Payment to Co in Connection With Effectiveness of Agreement

THOMSON REUTERS
·
21 Jan

Keros Therapeutics Announces Effectiveness of Global License Agreement With Takeda to Advance Elritercept

THOMSON REUTERS
·
21 Jan

Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept

GlobeNewswire
·
21 Jan

Wedbush Downgrades Keros Therapeutics to Neutral From Outperform

MT Newswires Live
·
18 Jan

Keros Therapeutics Inc : Wedbush Cuts to Neutral From Outperform; Cuts Target Price to $15 From $47

THOMSON REUTERS
·
18 Jan

Keros Therapeutics (KROS) Gets a Buy from Piper Sandler

TIPRANKS
·
17 Jan

U.S. RESEARCH ROUNDUP- Hubspot, Morgan Stanley, US Bancorp

Reuters
·
17 Jan

Keros Therapeutics Inc : Piper Sandler Cuts Target Price to $15 From $40

THOMSON REUTERS
·
17 Jan